Wilms' tumor gene 1 as an immunotherapeutic target in uterine cancer

Wilms' tumor gene 1 as an immunotherapeutic target in uterine cancer

Versandkostenfrei!
Versandfertig in 6-10 Tagen
29,99 €
inkl. MwSt.
PAYBACK Punkte
15 °P sammeln!
Uterine high grade sarcoma and recurrent endometrial carcinoma are aggressive cancers with limited classical treatment options, resulting in a poor prognosis. The search for targeted treatments is urgently needed. In this research we focused in the first place on the detection of the highly immunogenic tumor-associated antigen Wilms tumor gene 1 (WT1) in uterine tumors. The next step was to develop a targeted treatment against WT1, based on dendritic cell immunotherapy.